Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda febuxostat review delayed

Executive Summary

FDA is continuing to review Takeda's febuxostat NDA past the Jan. 18 user fee deadline. Febuxostat is being considered for the treatment of hyperuricemia in patients with gout; an advisory committee recommended approval (12-0 with one abstention) at a Nov. 24 meeting (1"The Pink Sheet," Dec. 1, 2008, p. 5). The committee expressed concern with a potential cardiovascular signal and encouraged FDA to use its post-approval authorities to require further study. FDA also missed the Oct. 24 user fee date for Takeda's alogliptin; that review is now expected to extend until June 2009 (2"The Pink Sheet" DAILY, Dec. 29, 2008)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS050600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel